David S. Shields is Named to CapsoVision’s Board

CapsoVision Inc. has appointed David S. Shields, M.D., to its Board of Directors. He is a board-certified gastroenterologist with more than 40 years of experience in academic medicine, clinical gastroenterology, advanced endoscopy, and digestive disease management.

“We are delighted to welcome David to our Board of Directors,” CapsoVision President/CEO Johnny Wang stated. “Since 2017, he has been a trusted clinical advisor to CapsoVision. As we approach several important milestones, including the anticipated commercial launch of our AI-assisted reading feature for CapsoCam Plus, the continued advancement of our second-generation CapsoCam Colon program, and the expected expansion of our broader capsule platform, we believe the company is entering an exciting new phase of growth. David’s deep clinical expertise, extensive experience in capsule endoscopy, and longstanding knowledge of gastrointestinal clinical practice make him an invaluable addition to our board.”

Dr. Shields has been a clinical advisor and consultant to CapsoVision for nearly a decade. He succeeds Joanne C. Imperial, M.D., who has stepped down from the board and will continue to support the company as an independent clinical consultant.

“On behalf of the board and the entire CapsoVision team, I want to thank Dr. Joanne Imperial for her many contributions as a director,” Wang said. “We are pleased that she will continue to support CapsoVision as a close clinical advisor, providing ongoing guidance for our pancreatic cancer clinical program and our planned 2027 esophageal varices study, which will evaluate our next-generation capsule platform incorporating Canon’s advanced imaging technology. We look forward to continuing to benefit from Joanne’s clinical expertise as we advance these important programs.”

Dr. Shields has maintained a private gastroenterology consulting practice in Palo Alto, Calif., since 1986, caring for patients with gastrointestinal and liver disorders. He previously served as assistant professor of Medicine in the Division of Gastroenterology at Stanford University School of Medicine and director of Endoscopy at Stanford Hospital. A recognized leader in gastrointestinal innovation, Dr. Shields established one of the earliest gastroenterology endoscopy programs at Stanford University and has been an early adopter and clinical investigator in capsule endoscopy technology. He currently serves as a gastroenterology consultant and clinician at both San Mateo County Medical Center and the Palo Alto Veterans Affairs Health Care System, where he continues to teach medical residents and gastroenterology fellows. Dr. Shields has nearly two decades of experience using capsule endoscopy to diagnose and manage small bowel disorders and gastrointestinal bleeding.

Dr. Shields earned a bachelor of arts degree in biochemistry with highest honors from the University of California, Santa Barbara, and received his Doctor of Medicine degree from the University of California, San Francisco School of Medicine. He completed his residency training in Internal Medicine at Stanford University School of Medicine and the University of Virginia, followed by a fellowship in gastroenterology at the University of Virginia.

“I am honored to join CapsoVision’s board at such an exciting time for the company,” Dr. Shields commented. “Having worked alongside the team for many years, I’ve seen firsthand the innovation behind its technology and its commitment to improving patient care. I believe CapsoVision is well positioned to advance the next generation of AI-enabled capsule endoscopy, and I look forward to helping guide the company’s continued growth and clinical impact.”

CapsoVision is a commercial-stage medical technology company developing advanced imaging and artificial intelligence (AI)-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus, is a wire-free, panoramic capsule endoscope that provides high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The company’s next pipeline product, CapsoCam Colon with enhanced AI, enables non-invasive colon imaging and polyp detection. CapsoVision’s proprietary platform is designed to expand across multiple GI indications, including esophageal and pancreatic disorders.